Comparison between Management and Pharmacotherapy of COVID-19 in Iran and Switzerland Management and Pharmacotherapy of COVID-19 in Iran and Switzerland
Novelty in Biomedicine,
Vol. 10 No. 4 (2022),
2 December 2022
,
Page 219-225
https://doi.org/10.22037/nbm.v10i4.38215
Abstract
Background: On 30 January 2020, the WHO declared the outbreak of SARS-CoV-2 as a public health
emergency. In the present study, we compared the preventative and therapeutic strategies and the success rates of Iran and Switzerland during the COVID-19 outbreak.
Materials and Methods: This study was conducted using electronic databases such as PubMed, Scopus, and
Web of Science. In addition, the official documents of developed countries and WHO from 1st February until 15th May 2020 were studied. Relevant documents were reviewed in detail, and vital data were extracted.
Results: Both countries have restriction policies to reduce the infection rate in the prevention setting. These
policies, such as the recommendation to all citizens to stay home unless necessary, army participation, and
non-face-to-face counseling, were surveyed by similar techniques in both countries. Some policies were
implemented in both countries with different protocols. These policies, including social distancing practices,
smart distancing methods, business activities, border closures, border controls, and restrictions, travel
restrictions, testing and screening for infection and fever, and decreased working hours, were performed in
both countries. In the treatment setting, the therapeutic strategy used in Iran consisted of hydroxychloroquine
or chloroquine phosphate and anti-viral drugs. Switzerland followed the guidelines of the European countries.
The infection rate, recovery rate, and death rate were 0.139%, 78.73%, and 5.91% in Iran, while these rates
were 0.352%, 88.81%, and 6.15% in Switzerland, respectively.
Conclusion: Due to the lack of special treatment for the disease, prevention must be considered the most
important factor in policymaking. Importantly, observing social distance is the most effective method among
the preventative strategies. The capacity of the health care systems to provide optimal services and facilities is
an important factor for patients recovery.
- Management and Pharmacotherapy, COVID-19, Iran, Switzerland
How to Cite
References
Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed
asymptomatic carrier transmission of COVID-19. Jama.
;323(14):1406-7.
Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W, et al. A
pneumonia outbreak associated with a new coronavirus of probable bat
origin. Nature. 2020;579:270-3.
Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the
cardiovascular system. Nature Reviews Cardiology. 2020;17(5):259-60.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features
of patients infected with 2019 novel coronavirus in Wuhan, China. The
lancet. 2020;395(10223):497-506.
Adhikari SP, Meng S, Wu Y-J, Mao Y-P, Ye R-X, Wang Q-Z, et al.
Epidemiology, causes, clinical manifestation and diagnosis, prevention
and control of coronavirus disease (COVID-19) during the early outbreak
period: a scoping review. Infectious diseases of poverty. 2020;9(1):1-12.
Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E,
Cornberg M, et al. Care of patients with liver disease during the COVID-
pandemic: EASL-ESCMID position paper. JHEP reports.
;2(3):100113.
Wu Y-C, Chen C-S, Chan Y-J. The outbreak of COVID-19: an
overview. Journal of the Chinese medical association. 2020;83(3):217.
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features,
evaluation, and treatment of coronavirus (COVID-19). Statpearls
[internet]. 2021.
Wu Z, McGoogan JM. Characteristics of and important lessons from
the coronavirus disease 2019 (COVID-19) outbreak in China: summary
of a report of 72 314 cases from the Chinese Center for Disease Control
and Prevention. Jama. 2020;323(13):1239-42.
Should we follow the Swiss in dealing with COVID-19? In.
Salathé M, Althaus CL, Neher R, Stringhini S, Hodcroft E, Fellay J,
et al. COVID-19 epidemic in Switzerland: on the importance of testing,
contact tracing and isolation. Swiss medical weekly. 2020;150(1112).
Reported cases and deaths by country, territory, or conveyance,
reported coronavirus cases. In; 2020.
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has
shown apparent efficacy in treatment of COVID-19 associated
pneumonia in clinical studies. Bioscience trends. 2020.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir
and chloroquine effectively inhibit the recently emerged novel
coronavirus (2019-nCoV) in vitro. Cell research. 2020;30(3):269-7.
- Abstract Viewed: 310 times
- pdf Downloaded: 236 times